Focalyx is a private MedTech software & medical device company focused on the diagnosis and treatment of prostate cancer. The company was founded in 2015 and is headquartered in the United States. Focalyx's flagship product is the Focalyx Fusion software, which supports computer-assisted surgical planning and provides real-time operative guidance during minimal invasive prostate procedures. The software brings an all-in-one solution into medical offices, offering AI-driven diagnostic & therapeutic targeted interventions. With a strong focus on the health care industry, Focalyx is positioned to make significant strides in the diagnosis and treatment of prostate cancer, addressing a crucial need in the medical field.
General Information
Get notified when Focalyx moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Focalyx
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Health Care
About Focalyx
Taxonomy: MedTech, medical device, prostate cancer, diagnosis, treatment, Focalyx Fusion software, surgical planning, minimal invasive procedures, AI-driven diagnostics, therapeutic interventions, computer-assisted surgery, prostate health, AI-guided treatments
No funding data available for Focalyx yet.
Get notified when Focalyx raises fundingFocalyx Alternatives & Competitors
Incision-Free, Ablative Interventions with Vision
Drug-Eluting Biopsy Needle will reduce infection rates in the 5M prostate biopsies performed each ye...
Medical device software using AI to find cancer precisely and fast with MRI, focusing on prostate ca...
FAQ About Focalyx
Don't just browse. Track.
Signal Tracker monitors Focalyx and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.